Datatrial Announces Partnership With Nexus Oncology
The collaboration will provide Datatrial and Nexus' clients with more effective management and delivery of oncology trials
Newcastle upon Tyne, United Kingdom & Raleigh, North Carolina – March 22, 2006 – Datatrial, an innovative provider of global data management solutions for the clinical research industry, announces an operational partnership with Nexus, a niche oncology contract research organization (CRO). The collaboration will provide Datatrial and Nexus' clients with more effective management and delivery of oncology trials.
As part of the agreement, Datatrial will provide Data Management and Biostatistical reporting services for Nexus, as well as Electronic Data Capture technology through its nowEDC™ and nowReport™ systems. The proprietary nowEDC™ system provides an online data collection tool focused on ease of use and efficiency at the investigative site, while providing dynamic functionality to the supporting clinical teams. The wizard-driven, XML reporting software, nowReport™, provides customers with continuous access to current trial data for precise decision making and patient safety management. Together they will provide Nexus with the tools to successfully execute and manage the most complicated oncology studies. Additionally, Datatrial will provide traditional Data Management and Biostatistical services utilizing Oracle Clinical and SAS tools.
Andrew MacGarvey, Vice President at Datatrial, commented, "Datatrial performed its first studies in the field of oncology, and has built on that experience in this complex area using our Electronic Data Capture system, nowEDC™, as well as traditional Data Management and Biostatistical services. Our relationship with Nexus Oncology allows us to provide a full range of services in this sector, and is already proving to be highly successful."
Clare Wareing, Founder and Managing Director of Nexus Oncology, added, "We are delighted to announce our partnership with Datatrial. It is a natural progression from our successful collaborations to date, and will help to ensure that Nexus Oncology continues to successfully manage and deliver its research. Applying Datatrial's strategies and solutions to our clinical trials will be a substantial asset to the biometrics process from data collection to reporting. This will benefit our client's development timelines while allowing us to manage data as effectively as possible."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
